Target
Somatostatin Receptors (SSTRs)
16 abstracts
Abstract
A phase II randomized control trial of triapine plus lutetium 177 DOTATATE versus lutetium 177 DOTATATE alone for well-differentiated somatostatin receptor-positive neuroendocrine tumors.Org: Markey Cancer Center, University of Kentucky HealthCare,
Abstract
Quality of life (QoL) benefits following 177Lu-DOTATATE therapy in patients (pts) with 68Ga-DOTATATE PET positive primary site agnostic neuroendocrine tumors (NET).Org: St. Joseph's Health Care, Division of Endocrinology and Metabolism,
Abstract
Safety, tolerability and efficacy of 212Pb-DOTAMTATE as a targeted alpha therapy for subjects with unresectable or metastatic somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors (SSTR+ GEP-NETs): A phase 2 study.Org: Excel Diagnostics Nuclear Oncology Center, RadioMedix Inc., Orano Med SAS,
Abstract
Prospective evaluation of the utility of concurrent 18F-FDG PET/CT and 68Ga-DOTA-TOC imaging in gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): The PETNET study.Org: BC Cancer-Vancouver Centre, Vancouver Cancer Centre, BC Cancer Research Institute, BCCA,
Abstract
Prevalence of intra-patient inter-metastatic heterogeneity in mCRPC patients based on triple-tracer PET imaging: The 3TMPO study.Org: Laval University, CHU de Quebec-Universite Laval, Division of Urology, Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, Centre Hospitalier de l’Université de Montréal (CHUM/CRCHUM), University of Sherbrooke,
Abstract
Implementation of a streamlined prior authorization process to improve cancer care delivery.Org: Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, Mount Sinai Health System, New York, NY, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, Mount Sinai Health System, NY, NY, Mount Sinai Health System, NY, NY, Icahn School of Medicine at Mount Sinai, New York, NY,
Abstract
Using real-world evidence (RWE) in regulatory decision making: A study of 6 oncology approvals with RWE included in the product label.Org: Bayer HealthCare Pharmaceuticals Inc., Bayer, Xcenda, Xcenda LLC, Bayer Corporation,
Abstract
Correlating peptidylglycine alpha-amidating monooxygenase (PAM) expression with clinicopathologic variables in gastrointestinal (GI) neuroendocrine tumors (NETs).Org: The Ottawa Hospital Research Institute, Ottawa Hospital Research Institute, The Ottawa Hospital Regional Cancer Centre, Baylor College of Medicine, The Ottawa Hospital Cancer Centre,
Abstract
Association of guideline adherence in diagnosis and treatment of pancreatic neuroendocrine tumors with survival.Org: Department of Hematology and Oncology with Palliative Care, St. Josef Hospital, Ruhr University, Bochum, Germany, Institute of Pathology, Ruhr University, Bochum, Germany, Department of General and Visceral Surgery, St. Josef Hospital, Ruhr University, Bochum, Germany,
Abstract
Real world sequence of peptide receptor radionucleotide therapy (PRRT) and chemotherapy in patients with metastatic pancreatic neuroendocrine tumors (pNETs).Org: University of Ottawa, London Health Science Centre, The Ottawa Hospital Research Institute, Western University, London Health Sciences Centre,
Abstract
Prognostic value of total tumor volume with 68Ga DOTATOC PET/CT in predicting response to 177-Lu-DOTATOC treatment in metastatic well-differentiated neuroendocrine tumors (NETs).Org: Instituto Nacional de Cancerolgia, Instituto Nacional de Cancerologia, Gastrointestinal Oncology Unit,
Abstract
The NETFIT trial: Smart wearable medical devices to assess the quality of life of patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NET).Org: Medical Oncology Group, Hospital Universitario Ramón y Cajal, MD Anderson Cancer Center, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, University Hospital Virgen del Rocío,
Abstract
Clinical and radiological criteria for candidate patients with small bowel neuroendocrine neoplasms (SB-NEN) for minimally invasive surgery: A single-centre experience.Org: Istituto Europeo di Oncologia IRCCS, European Institute of Oncology, IEO - Istituto Europeo di Oncologia IRCCS, Milan, Italy, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, European Institute of Oncology (IEO) IRCCS,
Abstract
Clinicopathological features and treatment patterns of patients with cancer of unknown primary site (CUP): Mayo Clinic experience.Org: Mayo Clinic, Mayo Clinic, Department of Laboratory Medicine and Pathology, Mayo Clinic, Mankato,
Abstract
Real world utilization and outcomes of immunotherapy regimens in metastatic castration resistant prostate cancer (mCRPC).Org: Tisch Cancer Institute, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY,
Abstract
177Lu-DOTATATE in neuroendocrine tumors: Real-world evidence of efficacy and safety in a community setting.Org: Scripps Mercy Hospital, Scripps Clinic/Scripps Green Hospital, Scripps Clinic/Green Hospital,